Stock Analysis
- United States
- /
- Medical Equipment
- /
- NasdaqGS:NVCR
NovoCure First Quarter 2024 Earnings: Beats Expectations
NovoCure (NASDAQ:NVCR) First Quarter 2024 Results
Key Financial Results
- Revenue: US$138.5m (up 13% from 1Q 2023).
- Net loss: US$38.8m (loss narrowed by 27% from 1Q 2023).
- US$0.36 loss per share (improved from US$0.50 loss in 1Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
NovoCure Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 5.4%. Earnings per share (EPS) also surpassed analyst estimates by 14%.
Looking ahead, revenue is forecast to grow 8.1% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US.
Performance of the American Medical Equipment industry.
The company's shares are up 16% from a week ago.
Risk Analysis
Don't forget that there may still be risks. For instance, we've identified 1 warning sign for NovoCure that you should be aware of.
Valuation is complex, but we're helping make it simple.
Find out whether NovoCure is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqGS:NVCR
NovoCure
An oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally.
Adequate balance sheet and slightly overvalued.